Besides numerous other factors, fibroblast growth factor receptor (FGFR) signaling is involved in fracture healing and bone remodeling. FGF23 is a phosphatonin produced by osteoblastic cells, which signals via FGFR1, thereby exerting effects in bone and kidney. We analyzed if serum FGF23 levels might be an indicator to predict fracture healing and union. FGF23 (C-Term) was elevated on day 3 postoperatively in 55 patients sustaining an exchange of total hip implants due to aseptic loosening. A prospective study of 40 patients undergoing primary hip arthroplasty also showed elevated FGF23 (C-Term) but no change in FGF23 (intact) levels on days 1, 4, and 10 postoperatively. Serum phosphate and phosphate clearance stayed within normal ranges. FGF23 mRNA expression in ovine callus was compared between a standard and delayed course of osteotomy healing. In the standard model, a marked increase in FGF23 mRNA expression compared to the delayed healing situation was observed. Immunohistochemical analysis showed FGF23 production of osteoblasts and granulation tissue in the fracture callus during bone healing. In conclusion, FGF23 is involved in bone healing, can be measured by a sensitive assay in peripheral blood, and is a promising candidate as an indicator for healing processes prone to reunion versus nonunion. Keywords: fibroblast growth factor 23; fracture healing; phosphate; arthroplasty Fibroblast growth factor 23 (FGF23) is a FGF family member that is expressed mainly in osteocytes. In pathophysiological conditions such as fibrous dysplasia osteoblasts and preosteoblasts are reported to produce FGF23. 1 The expression of FGF23 in chondrocytes, osteoclasts, and pericytes has also been shown.2 FGF23 signals are mediated via the FGF receptor 1(IIIc): the combined binding of FGF23 and the antiageing hormone Klotho has been shown to convert FGFR1 to an FGF23-specific receptor.3-7 FGF23 was originally identified and cloned as a causative factor for tumor induced osteomalacia (TIO), where mostly benign tumors overexpress phosphaturic factors such as FGF23, which causes renal phosphate wasting. [8][9][10] High FGF23 concentrations are associated with impaired 1a-hydroxylase activity in the kidney, leading to low 1,25(OH)2 vitamin D3 levels. [11][12][13] Additionally, the expression of the renal sodium phosphate transporters Npt1, Npt2a, and NPT2c is down-regulated by FGF23, thereby influencing the systemic regulation of phosphate metabolism.14,15 The FGF23 gene is linked to several inheritable syndromes such as autosomal dominant hypophosphatemic rickets (ADHR, gain of function mutations) and tumoral calcinosis (TC, loss of function mutations). ADHR results from a lack in protein processing by subtilisin-like-proteases due to a mutated RXXR cleavage motif within the protein structure. [16][17][18] TC is caused by either a mutation in GALNT3, a glycosyltransferase responsible for FGF23 glycosylation, or a mutation in a highly conserved FGF23 region resulting in decreased secretion. [19][20][21] Besides its functi...
of the effects of androgens and training on myostatin propeptide and follistatin concentrations in blood and skeletal muscle using highly sensitive Immuno PCR. Molecular and Cellular Endocrinology, Elsevier, 2010, 330 (1-2) This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with đź’™ for researchers
Part of the Research Solutions Family.